{"id":"ntx-pbo-b","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Nausea"},{"rate":"20–30","effect":"Constipation"},{"rate":"15–25","effect":"Headache"},{"rate":"10–20","effect":"Dizziness"},{"rate":"10–15","effect":"Insomnia"},{"rate":"5–10","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL195316","moleculeType":"Small molecule","molecularWeight":"355.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naltrexone blocks opioid receptors in the hypothalamus, removing tonic inhibition of pro-opiomelanocortin (POMC) neurons that regulate satiety. Bupropion, a norepinephrine-dopamine reuptake inhibitor, enhances the activity of these POMC neurons. Together, the combination increases energy expenditure and decreases hunger, leading to sustained weight reduction.","oneSentence":"NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:29.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in obese or overweight adults with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT02537574","phase":"PHASE3","title":"Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-08","conditions":"Opioid Use Disorder","enrollment":380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NTX/PBO-B","genericName":"NTX/PBO-B","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss. Used for Chronic weight management in obese or overweight adults with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}